This episode reviews the 2025 ACE consensus approach to cost conscious obesity pharmacotherapy, emphasizing access driven treatment sequencing, payer mandated step therapy, and stage based medication selection for adiposity based chronic disease. Focus is placed on balancing clinical efficacy, affordability, and long term sustainability, with escalation and override strategies guided by therapeutic response and the presence of obesity related complications.

This episode reviews the 2025 ACE consensus on complication centric obesity management, with a focus on organ system based medication prioritization. Topics include pharmacologic selection across cardiometabolic, renal, hepatic, cardiovascular, and biomechanical complications, emphasizing outcome driven therapy rather than weight alone in adiposity based chronic disease (ABCD).

This episode reviews the 2025 ACE consensus on biologically informed lifestyle therapy for obesity and adiposity based chronic disease (ABCD), including personalized nutrition strategies to achieve and sustain an energy deficit, protein and micronutrient requirements to preserve lean mass and metabolic health, physical activity and resistance training targets for weight maintenance, the role of sleep and circadian regulation in energy balance, and the importance of addressing weight bias, stigma, and psychological comorbidities in long term obesity management.

This episode reviews the 2025 ACE consensus on therapeutic weight loss response, threshold based outcomes, early pharmacologic response assessment, and how to align intervention intensity with disease severity in adiposity based chronic disease (ABCD).

This episode reviews the clinical component of the 2025 ACE consensus, shifting from identifying excess adiposity to staging adiposity based chronic disease (ABCD). It explains how clinicians assess obesity related complications, apply disease staging independent of BMI, and account for contributing factors such as medications, endocrine causes, genetics, psychological influences, and social determinants. The episode then connects staging to individualized treatment planning and long term management within a chronic disease framework.

This episode examines the anthropometric component of the 2025 ACE consensus on obesity, emphasizing the role of BMI as a screening tool rather than a diagnostic endpoint. It outlines population specific BMI thresholds, the clinical need for assessing abdominal adiposity, and the importance of standardized waist circumference and waist to height ratio measurements in evaluating cardiometabolic risk. The discussion reinforces why body fat distribution, rather than total body weight, drives disease risk and explains when body composition testing is indicated to clarify clinical ambiguity. The episode situates these measurements within the broader ACE framework for adiposity based chronic disease (ABCD), supporting more accurate risk stratification and individualized management.

This episode introduces the 2025 ACE consensus framework for obesity, reframing the condition as adiposity based chronic disease (ABCD) rather than a numeric weight diagnosis. It reviews the shift toward person centered, complication centric care, emphasizing the role of both anthropometric and clinical assessment in diagnosis and staging. The discussion highlights obesity related complications as the primary driver of disease severity, the limitations of body mass index as an endpoint, and the importance of shared decision making and longitudinal management using lifestyle, pharmacologic, and surgical therapies to improve health outcomes and quality of life.

This episode reviews the management of dyslipidemia in special populations using an individualized, risk based framework. It emphasizes ASCVD risk assessment in older adults, patients receiving gender affirming hormone therapy, individuals living with HIV, those with chronic inflammatory or autoimmune diseases, adult survivors of childhood cancer, and solid organ transplant recipients. The discussion highlights statin selection, drug drug interactions, use of non statin therapies, and the limitations of traditional risk calculators, underscoring the importance of shared decision making and tailored lipid lowering strategies in populations with complex and often underestimated cardiovascular risk.

This episode reviews guideline directed statin therapy and LDL lowering strategies using ASCVD risk based statin benefit groups. It emphasizes selection of statin intensity, LDL C treatment targets, and appropriate escalation to non statin therapies, including ezetimibe, PCSK9 inhibitors, and bempedoic acid. The episode also addresses statin associated muscle symptoms, CK based management thresholds, and evidence based approaches to true statin intolerance with shared decision making for optimal cardiovascular risk reduction.

This episode reviews the management of hypertriglyceridemia in pregnancy using a triglyceride level guided framework. It emphasizes risk stratification for maternal ASCVD versus pancreatitis, identification of secondary and genetic dyslipidemias, and implementation of lifestyle, dietary, and pharmacologic interventions with multidisciplinary oversight throughout gestation and lactation.